Form 4: Nurix CSO's Mandatory Stock Sale for Tax Obligations

Nurix Therapeutics' Chief Scientific Officer, Gwenn Hansen, reported the vesting of restricted stock units and a subsequent mandatory 'sell to cover' transaction to satisfy tax obligations.

Summary

• Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, Inc. (NRIX), reported transactions on October 30, 2025.
• Acquired a total of 11,815 shares of common stock through the vesting of Restricted Stock Units (RSUs) at an exercise price of $0.
• Disposed of 4,087 shares of common stock through a sale at a weighted average price of $12.7967.
• The sale was mandated by the Issuer's equity incentive plans to cover tax withholding obligations associated with the RSU vesting, not a discretionary trade.
• The lowest price at which shares were sold was $12.68, and the highest was $12.89.
• Following these transactions, Gwenn Hansen beneficially owns 76,751 shares of Nurix Therapeutics common stock.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to RSU vesting and mandatory tax-related stock sales, which are not indicative of discretionary sentiment or a change in the company's fundamental outlook.

Positives

• The vesting of 11,815 Restricted Stock Units (RSUs) indicates the successful fulfillment of compensation milestones for the Chief Scientific Officer.
• The RSU vesting and subsequent share delivery reinforce the company's equity incentive plans as a mechanism for executive retention and alignment of interests.

Negatives

• The sale of 4,087 shares, while mandatory for tax purposes, results in a reduction of the insider's direct common stock holdings.

Future Outlook

NA

Management Comments

• The sales reported represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ('RSUs').
• These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person.

Industry Context

This Form 4 filing details a routine insider transaction related to executive compensation, which is common across publicly traded companies, particularly in the biotechnology sector where equity incentives are a significant component of compensation packages. It does not provide specific insights into broader industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: The sale of shares for tax purposes is a minor dilution event, but it is a standard and expected part of equity compensation plans and is unlikely to have a significant impact on the broader shareholder base.
• Employees: The vesting of RSUs demonstrates the company's commitment to its equity incentive programs, which can positively impact employee morale and retention, particularly for key executives.

Next Steps

• Future vesting increments of Restricted Stock Units will continue according to the established schedules, subject to the Reporting Person's continued provision of services to the Issuer.

Key Dates

Recommendation

The Form 4 details a routine, non-discretionary transaction by a company executive to cover tax liabilities arising from RSU vesting. This event does not provide new fundamental information about Nurix Therapeutics, Inc. that would warrant a change in investment stance. Therefore, a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Nurix Therapeutics, NRIX, Form 4, Insider Transaction, RSU Vesting, Sell to Cover, Gwenn Hansen, Chief Scientific Officer, Equity Compensation